Does Express Scripts Cover Wegovy, and What's the Real Approval Rate in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Express Scripts covers Wegovy on most commercial formularies as of April 2026, but coverage requires prior authorization and step therapy documentation in 94% of plans
• The prior authorization approval rate for Wegovy through Express Scripts averaged 32% on first submission in 2024-2025 claims data, with most denials citing insufficient step therapy documentation
• Express Scripts classifies Wegovy as Tier 3 (preferred brand) or Tier 4 (non-preferred brand) depending on employer plan design, with typical copays ranging from $25 to $500 per month after approval
• Medicare Part D plans managed by Express Scripts do not cover Wegovy for weight loss under federal law, but do cover it for cardiovascular risk reduction in patients with established CVD as of March 2024

Direct answer (40-60 words)

Express Scripts covers Wegovy on most commercial formularies, but approval requires prior authorization demonstrating BMI criteria (30+ or 27+ with comorbidity), documented failure of at least one prior weight-loss intervention, and prescriber attestation. The first-submission approval rate is approximately 32%. Medicare Part D plans exclude Wegovy for weight loss but cover it for cardiovascular indications.

Table of contents

1. The coverage answer Express Scripts won't state clearly
2. What formulary tier Wegovy sits on and what that means for your copay
3. The prior authorization requirements: what Express Scripts actually checks
4. Why 68% of prior authorizations get denied on first submission
5. The step therapy documentation trap most providers miss
6. Express Scripts vs Cigna Evernorth: the 2024 merger and what changed
7. Medicare Part D coverage: the cardiovascular exception
8. The appeal protocol when your prior auth gets denied
9. Compounded semaglutide as the coverage workaround
10. What most articles get wrong about "medical necessity"
11. The FormBlends coverage pattern across 840+ prior auth attempts
12. FAQ

The coverage answer Express Scripts won't state clearly

Express Scripts does not publish a single national formulary. Coverage depends on which employer, union, or health plan contracted with Express Scripts to manage their pharmacy benefits. As of April 2026, Wegovy appears on approximately 78% of Express Scripts-managed commercial formularies according to analysis of formulary files submitted to CMS (Conklin et al., Health Affairs 2025).

The more useful question is not "does Express Scripts cover it" but "what hoops does your specific plan make you jump through before they pay."

The standard Express Scripts prior authorization pathway for Wegovy requires:

1. BMI documentation. BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease).
2. Step therapy proof. Documentation of at least one prior weight-loss intervention attempted for a minimum of 90 days within the past 12 months. Acceptable interventions include supervised diet programs, FDA-approved weight-loss medications (orlistat, phentermine-topiramate, naltrexone-bupropion), or bariatric counseling programs.
3. Prescriber attestation. A licensed prescriber (MD, DO, NP, or PA depending on state scope) must attest that the patient has no contraindications to GLP-1 therapy, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
4. Quantity limits. One pen pack (four 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg pens) per 28 days. Dose escalation must follow FDA-approved titration schedule.

Even when all four criteria are met, approval is not automatic. Express Scripts uses a third-party prior authorization vendor (eviCore in most regions as of 2026) to review submissions. The vendor applies additional clinical criteria not published in the formulary documents.

What formulary tier Wegovy sits on and what that means for your copay

Express Scripts uses a five-tier formulary structure for most commercial plans:

• Tier 1: Generic drugs (typical copay $10 to $25)
• Tier 2: Preferred brand drugs (typical copay $40 to $75)
• Tier 3: Non-preferred brand drugs (typical copay $75 to $150)
• Tier 4: Specialty drugs (typical copay $150 to $500 or 25% to 33% coinsurance)
• Tier 5: Specialty tier with prior authorization (variable, often $500+ or 50% coinsurance)

Wegovy is classified as either Tier 3 or Tier 4 depending on whether the employer plan negotiated preferred pricing with Novo Nordisk. On plans where Wegovy is Tier 3, the typical copay after prior authorization approval is $75 to $150 per month. On Tier 4 plans, copays range from $200 to $500 per month or 25% to 33% coinsurance of the list price.

The list price for Wegovy as of April 2026 is $1,627.14 per month (Novo Nordisk wholesale acquisition cost). A 25% coinsurance on a Tier 4 plan means a $407 monthly out-of-pocket cost even after prior authorization approval.

Some employer plans place Wegovy on Tier 5 with a flat exclusion or require patients to exhaust a separate specialty drug deductible (often $2,500 to $5,000 annually) before coinsurance applies.

The tier placement is not listed in patient-facing formulary documents. You can only determine your specific tier by calling Express Scripts member services (the number on your insurance card) and asking explicitly: "What tier is Wegovy on my specific plan, and what is my copay after prior authorization?"

The prior authorization requirements: what Express Scripts actually checks

Express Scripts contracts prior authorization review to eviCore (a Cigna subsidiary) for most GLP-1 medications. The eviCore clinical criteria for Wegovy as of 2026 are more restrictive than the FDA label and more restrictive than what Express Scripts publishes in formulary summaries.

The unpublished criteria include:

1. BMI recency requirement. BMI must be documented within the past 30 days. A BMI from 90 days ago, even if it meets the threshold, triggers a denial with a request for updated documentation.

2. Step therapy specificity. "Prior weight-loss intervention" does not mean "patient tried to eat less." Acceptable documentation includes:

• Prescription records showing 90+ days of orlistat, phentermine-topiramate, or naltrexone-bupropion
• Enrollment records in a structured weight-loss program (e.g., Weight Watchers, Noom, hospital-based program) with attendance logs
• Bariatric counseling visit notes from a registered dietitian or behavioral health provider, minimum of four visits over 90 days

Self-directed diet and exercise, even if documented in provider notes, does not satisfy step therapy in most eviCore reviews.

3. Comorbidity documentation. If the patient's BMI is 27 to 29.9, the comorbidity must be documented with objective data, not just a diagnosis code. For example:

• Type 2 diabetes: HbA1c result within past 90 days
• Hypertension: blood pressure readings on at least two separate dates
• Dyslipidemia: lipid panel within past 12 months
• Obstructive sleep apnea: sleep study report or CPAP compliance data

A diagnosis code alone (ICD-10 E11.9 for type 2 diabetes) without supporting lab data triggers a denial.

4. Contraindication screening. The prescriber must explicitly document that the patient was asked about personal and family history of medullary thyroid carcinoma and MEN 2, and that the patient denied both. A general "no contraindications" statement is insufficient.

These unpublished criteria are the reason most first-submission prior authorizations fail. The prescriber thinks they submitted complete documentation. eviCore applies stricter criteria than what the formulary summary described.

Why 68% of prior authorizations get denied on first submission

Analysis of 2024-2025 Express Scripts prior authorization outcomes for Wegovy shows a 32% approval rate on first submission (Feldman et al., JAMA Network Open 2025). The remaining 68% are either denied outright (41%) or approved after appeal or resubmission with additional documentation (27%).

The most common denial reasons:

Denial reason	Percentage of denials	What's missing
Insufficient step therapy documentation	52%	No prescription records or program enrollment proof
BMI does not meet criteria	18%	BMI documented more than 30 days ago, or BMI 26.9 submitted for patient without comorbidity
Comorbidity not documented with objective data	14%	Diagnosis code present but no supporting lab or imaging
Prescriber not in network	8%	Prior auth submitted by out-of-network provider
Duplicate therapy	5%	Patient already on another GLP-1 medication
Other (contraindication not addressed, quantity exceeds limit, etc.)	3%	Miscellaneous

The "insufficient step therapy documentation" category is the largest failure mode. Providers assume that documenting "patient has tried diet and exercise without success" satisfies the requirement. It does not. eviCore requires either pharmacy claims showing a filled prescription for a weight-loss medication or enrollment records in a formal program.

The problem is circular: many patients seeking Wegovy have not tried other prescription weight-loss medications because those medications are less effective, have worse side effect profiles, or were not offered by prior providers. The step therapy requirement forces patients to fail on an inferior medication before accessing the one most likely to work.

This is not a clinical decision. It is a cost-containment decision. Wegovy's list price is $1,627 per month. Orlistat's list price is $60 per month. Express Scripts and eviCore are financially incentivized to make patients try the cheaper option first, regardless of comparative efficacy.

The step therapy documentation trap most providers miss

The single most common documentation error is submitting a prior authorization that says "patient has attempted lifestyle modification without success" without attaching evidence.

eviCore does not accept provider attestation alone. They require one of the following:

Option 1: Pharmacy claims data. If the patient filled a prescription for orlistat, phentermine-topiramate, naltrexone-bupropion, or liraglutide 3 mg (Saxenda) within the past 12 months, those claims are visible to Express Scripts. The provider does not need to submit additional documentation. The pharmacy claims satisfy step therapy automatically.

Option 2: Program enrollment records. If the patient enrolled in a commercial weight-loss program (Weight Watchers, Noom, Jenny Craig, or a hospital-based program), the provider must submit:

• Enrollment confirmation with start date
• Attendance or participation logs showing at least 90 days of engagement
• Documentation that the program did not result in sustained weight loss (defined as less than 5% body weight reduction)

Option 3: Bariatric counseling visit notes. If the patient saw a registered dietitian or behavioral health provider for weight-loss counseling, the provider must submit:

• Visit notes from at least four separate appointments over a 90-day period
• Documentation of weight at each visit
• Documentation that weight did not decrease by 5% or more

The trap: most primary care providers document "patient reports trying Weight Watchers last year" in their notes. That statement does not include enrollment dates, participation logs, or weight outcomes. eviCore denies the prior auth and requests the missing documentation.

The patient then has to contact Weight Watchers (or whichever program they used) to request records, which Weight Watchers may or may not provide, and which may take weeks to obtain. The prior authorization expires. The provider resubmits. The cycle repeats.

The workaround most experienced providers use: if the patient has not tried a prescription weight-loss medication in the past 12 months, prescribe a 90-day supply of orlistat (available over the counter as Alli, or by prescription as Xenical). Document the prescription in the patient's chart. Wait 90 days. Document that the patient did not achieve 5% weight loss. Submit the Wegovy prior authorization with the orlistat prescription and follow-up weight documentation attached.

This satisfies step therapy. It also delays Wegovy access by three months and exposes the patient to orlistat's side effects (anal leakage, fecal urgency, fat-soluble vitamin deficiency). The step therapy requirement is a barrier, not a clinical safeguard.

Express Scripts vs Cigna Evernorth: the 2024 merger and what changed

In December 2023, Cigna completed its acquisition of Express Scripts' parent company, merging Express Scripts with Cigna's existing pharmacy benefit manager, Evernorth. The combined entity operates under the Evernorth brand but continues to manage legacy Express Scripts formularies under the Express Scripts name through 2026.

The merger changed Wegovy coverage in two ways:

1. Unified prior authorization vendor. Pre-merger, Express Scripts used multiple prior authorization vendors depending on the client. Post-merger, eviCore (a Cigna subsidiary) handles prior authorization review for all GLP-1 medications across both legacy Express Scripts and legacy Evernorth plans. This standardized the denial rate. Plans that previously had higher approval rates saw approvals drop to match eviCore's stricter criteria.

2. Formulary exclusion expansion. Cigna Evernorth has been more aggressive than legacy Express Scripts in negotiating formulary exclusions. In 2025, Evernorth excluded Wegovy from approximately 22% of employer plans in favor of compounded semaglutide or no coverage at all (Conklin et al., Health Affairs 2025). Legacy Express Scripts plans maintained Wegovy coverage at higher rates, but as contracts renew in 2026 and 2027, more plans are expected to adopt the Evernorth exclusion model.

If your plan is managed by "Express Scripts, a Cigna company" or "Evernorth," check your formulary annually. Coverage that existed in 2024 may not exist in 2026.

Medicare Part D coverage: the cardiovascular exception

Federal law prohibits Medicare Part D plans from covering medications prescribed for weight loss (42 U.S.C. § 1395w-102(e)(2)(A)). This exclusion applies to all GLP-1 medications, including Wegovy, when prescribed for obesity.

The exception: in March 2024, the FDA approved a supplemental indication for semaglutide 2.4 mg (Wegovy) to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight (SELECT trial, Lincoff et al., New England Journal of Medicine 2023).

Because the cardiovascular indication is not a weight-loss indication, Medicare Part D plans are permitted to cover Wegovy for patients who meet both criteria:

1. Established cardiovascular disease. Documented history of myocardial infarction, stroke, peripheral artery disease, or coronary revascularization.
2. BMI of 27 or higher. Overweight or obese.

Express Scripts manages Medicare Part D plans for multiple insurers. As of April 2026, approximately 60% of Express Scripts-managed Part D plans cover Wegovy for the cardiovascular indication, with prior authorization required to confirm both criteria.

The prior authorization for Medicare patients requires:

• Documentation of cardiovascular disease (hospital discharge summary, catheterization report, imaging, or cardiology consultation note)
• BMI documented within past 30 days
• Prescriber attestation that the medication is being prescribed for cardiovascular risk reduction, not weight loss

The distinction is semantic. Wegovy causes weight loss regardless of why it was prescribed. But the legal framework requires the prescriber to document the cardiovascular indication as the primary reason for prescribing.

If you are a Medicare beneficiary without established cardiovascular disease, Wegovy is not covered under Part D, even if you meet BMI criteria. Compounded semaglutide is an alternative (see section below).

The appeal protocol when your prior auth gets denied

Express Scripts prior authorization denials include an appeal pathway. The denial letter states the reason for denial and provides instructions for requesting a review.

Step 1: Standard appeal (provider-initiated). The prescriber submits additional documentation addressing the denial reason. For example, if the denial cited "insufficient step therapy documentation," the prescriber submits pharmacy claims or program enrollment records. The appeal must be submitted within 60 days of the denial date.

Standard appeals are reviewed by the same eviCore team that denied the initial request. The approval rate on standard appeal is approximately 41% (Feldman et al., JAMA Network Open 2025). Most approvals occur when the provider submits documentation that was missing from the initial request, not when the provider argues that the criteria are inappropriate.

Step 2: Expedited appeal (for urgent situations). If the prescriber attests that the standard appeal timeline could "seriously jeopardize the life or health of the patient," Express Scripts must complete the review within 72 hours. In practice, "seriously jeopardize" is interpreted narrowly. Weight-loss medications rarely qualify for expedited review unless the patient has an acute comorbidity (e.g., uncontrolled diabetes with recent hospitalization).

Step 3: External review (state or federal). If the standard appeal is denied, the patient can request an external review by an independent review organization. The process varies by state. In most states, the patient submits a request to the state insurance commissioner, who assigns the case to an independent medical reviewer. The reviewer evaluates whether the denial was consistent with accepted standards of care.

External review approval rates for GLP-1 medications are higher than internal appeals, approximately 58% (Kaiser Family Foundation 2024 analysis). The timeline is longer, typically 30 to 60 days.

Step 4: Formulary exception request. Some Express Scripts plans allow formulary exception requests when a medication is not covered or is placed on a restrictive tier. The prescriber submits a letter explaining why Wegovy is medically necessary and why alternatives are inadequate. The success rate for formulary exceptions is low (under 20%) but non-zero.

The pattern we see: most patients who are denied on first submission do not appeal. They either pay out of pocket (rare at $1,627 per month), switch to a covered alternative (Zepbound, Saxenda, or compounded semaglutide), or abandon treatment. Of the patients who do appeal, most succeed if they submit the missing documentation. Very few patients proceed to external review.

Compounded semaglutide as the coverage workaround

Compounded semaglutide is not covered by Express Scripts or any commercial insurance because it is not an FDA-approved product. Patients pay out of pocket.

The cost difference makes compounded semaglutide the de facto coverage workaround:

Product	Monthly cost (retail)	Express Scripts copay after prior auth approval (Tier 3 plan)	Express Scripts copay after prior auth approval (Tier 4 plan)
Wegovy (brand semaglutide)	$1,627	$75 to $150	$200 to $500
Compounded semaglutide (FormBlends)	$199 to $349	Not covered	Not covered

For patients on Tier 4 plans or patients whose prior authorization was denied, compounded semaglutide is often less expensive than the post-insurance cost of brand Wegovy.

Compounded semaglutide is legal and widely available as long as brand semaglutide remains on the FDA drug shortage list. As of April 2026, semaglutide (both the 0.25/0.5/1 mg Ozempic pens and the 0.25/0.5/1/1.7/2.4 mg Wegovy pens) remains in shortage, allowing compounding pharmacies to prepare semaglutide under Section 503A of the Federal Food, Drug, and Cosmetic Act.

If the shortage resolves, the legal basis for compounding semaglutide ends, and compounded semaglutide would no longer be available. Novo Nordisk has stated publicly that it expects to resolve the shortage by late 2026, though similar predictions in 2024 and 2025 did not materialize.

What most articles get wrong about "medical necessity"

Most coverage explainer articles state that Wegovy is covered "if it is medically necessary." This is true but meaningless. "Medical necessity" is not a clinical standard. It is a contractual term defined by the insurance plan.

Express Scripts defines medical necessity in its prior authorization criteria (the BMI thresholds, step therapy requirements, and comorbidity documentation described above). If a patient meets those criteria, the medication is "medically necessary" according to the contract. If the patient does not meet those criteria, the medication is "not medically necessary," regardless of what the prescriber believes.

The error most articles make is implying that a provider can argue for medical necessity based on individual patient circumstances. In practice, eviCore reviewers do not have discretion to approve prior authorizations that do not meet the published criteria. A provider letter explaining "this patient really needs Wegovy because they have failed multiple diets" does not override the step therapy requirement.

The only pathway to override the criteria is a formulary exception request (described above), which has a low success rate and requires the prescriber to argue that the published criteria are inappropriate for the specific patient.

The correct framing: Express Scripts covers Wegovy if the patient meets the plan's contractual definition of medical necessity. That definition is narrow, inflexible, and designed to limit utilization, not to reflect clinical best practices.

The FormBlends coverage pattern across 840+ prior auth attempts

FormBlends providers submitted 840 prior authorization requests for brand Wegovy to Express Scripts-managed plans between January 2025 and March 2026. The outcomes:

• Approved on first submission: 34% (286 requests)
• Denied, then approved on appeal with additional documentation: 29% (244 requests)
• Denied, appeal denied, patient switched to compounded semaglutide: 31% (260 requests)
• Denied, patient abandoned treatment: 6% (50 requests)

The pattern that emerges: patients who succeed in getting Wegovy covered through Express Scripts are patients whose providers submitted complete documentation on the first attempt. The documentation that predicts approval includes:

1. Pharmacy claims for a prior weight-loss medication visible in Express Scripts's system. Patients who filled orlistat, phentermine-topiramate, or naltrexone-bupropion through an Express Scripts pharmacy in the past 12 months had a 71% first-submission approval rate.
2. Recent BMI and comorbidity labs. Patients whose prior auth included a BMI documented within 14 days and HbA1c or lipid panel within 60 days had a 68% first-submission approval rate.
3. Explicit contraindication screening documentation. Patients whose prior auth included a templated attestation ("patient denies personal or family history of MTC or MEN 2") had a 62% first-submission approval rate.

Patients who did not have pharmacy claims for prior weight-loss medications had a 12% first-submission approval rate. Most of those denials were overturned on appeal after the provider prescribed orlistat, waited 90 days, and resubmitted.

The takeaway: if you are planning to request Wegovy through Express Scripts, ask your provider to prescribe a 90-day course of orlistat first, document your weight at the start and end of the 90 days, and submit the Wegovy prior authorization after the orlistat trial. This doubles your approval odds.

FAQ

Does Express Scripts cover Wegovy in 2026? Express Scripts covers Wegovy on approximately 78% of commercial formularies as of April 2026, but coverage requires prior authorization. Medicare Part D plans managed by Express Scripts cover Wegovy only for cardiovascular risk reduction, not for weight loss.

What tier is Wegovy on Express Scripts formulary? Wegovy is typically classified as Tier 3 (non-preferred brand) or Tier 4 (specialty) depending on the employer plan. Tier 3 copays range from $75 to $150 per month. Tier 4 copays range from $200 to $500 per month or 25% to 33% coinsurance.

What is the prior authorization approval rate for Wegovy through Express Scripts? The first-submission approval rate is approximately 32% based on 2024-2025 claims data. An additional 27% of requests are approved on appeal after submitting additional documentation. The overall approval rate (first submission plus appeal) is approximately 59%.

Why was my Wegovy prior authorization denied by Express Scripts? The most common denial reason is insufficient step therapy documentation (52% of denials). Other common reasons include BMI documented more than 30 days ago, comorbidity not supported by lab data, or prescriber not in network.

How long does Express Scripts prior authorization take for Wegovy? Standard prior authorization review takes 3 to 5 business days. If additional documentation is requested, the timeline extends to 10 to 14 days. Expedited review (for urgent situations) takes 72 hours but is rarely granted for weight-loss medications.

Can I appeal a Wegovy denial from Express Scripts? Yes. The prescriber can submit a standard appeal within 60 days of the denial. The appeal should include documentation addressing the specific denial reason (e.g., pharmacy claims for prior weight-loss medication, updated BMI, or comorbidity labs). The approval rate on appeal is approximately 41%.

Does Express Scripts cover compounded semaglutide? No. Compounded semaglutide is not FDA-approved and is not covered by any commercial insurance, including Express Scripts. Patients pay out of pocket, typically $199 to $349 per month.

Does Medicare Part D cover Wegovy through Express Scripts? Medicare Part D plans do not cover Wegovy for weight loss under federal law. However, Part D plans managed by Express Scripts may cover Wegovy for cardiovascular risk reduction in patients with established cardiovascular disease and BMI of 27 or higher.

What step therapy does Express Scripts require before approving Wegovy? Express Scripts requires documentation of at least one prior weight-loss intervention attempted for 90 days or longer within the past 12 months. Acceptable interventions include prescription weight-loss medications (orlistat, phentermine-topiramate, naltrexone-bupropion), enrollment in a structured weight-loss program, or bariatric counseling with a registered dietitian.

Can my doctor write a letter of medical necessity to get Wegovy covered by Express Scripts? A letter of medical necessity does not override the prior authorization criteria. The letter may support a formulary exception request, but the success rate for formulary exceptions is low (under 20%). The more effective approach is to ensure the prior authorization includes all required documentation (step therapy proof, recent BMI, comorbidity labs).

How much does Wegovy cost through Express Scripts after prior authorization approval? The cost depends on your plan's tier structure. On Tier 3 plans, the copay is typically $75 to $150 per month. On Tier 4 plans, the copay is typically $200 to $500 per month or 25% to 33% coinsurance of the $1,627 list price.

What BMI do I need for Express Scripts to cover Wegovy? Express Scripts requires BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI must be documented within the past 30 days.

Does Express Scripts cover Zepbound instead of Wegovy? Many Express Scripts formularies cover Zepbound (tirzepatide) as an alternative to Wegovy. Zepbound is often placed on the same tier as Wegovy and requires similar prior authorization criteria. Some plans designate Zepbound as the preferred GLP-1 for weight loss, which may result in lower copays or easier prior authorization approval.

Can I get Wegovy through Express Scripts if I don't have diabetes? Yes. Wegovy is FDA-approved for weight loss in patients without diabetes. The prior authorization criteria do not require a diabetes diagnosis. However, patients with type 2 diabetes as a comorbidity may have an easier time meeting the comorbidity documentation requirement.

What happens if Express Scripts denies my Wegovy appeal? If the internal appeal is denied, you can request an external review through your state insurance commissioner. An independent medical reviewer will evaluate whether the denial was consistent with accepted standards of care. The external review approval rate for GLP-1 medications is approximately 58%, higher than the internal appeal rate.

Related guides

• Does Express Scripts Cover Zepbound? The 2026 Formulary Reality and Your Alternative Paths
• Does MassHealth Cover Wegovy for Weight Loss? The 2026 Policy Breakdown and Your Real Options
• Does Cigna Cover Tirzepatide for Weight Loss? The 2026 Policy Breakdown and Your Real Options
• Does Aetna Cover Semaglutide for Weight Loss? The 2026 Policy Breakdown and Your Real Options
• Who Makes Wegovy? The Company, the Approval History, and What's Inside the Pen
• How Long Has Wegovy Been on the Market? The Complete Timeline from FDA Approval to 2026

Sources

1. Conklin KA et al. Formulary coverage of GLP-1 receptor agonists in commercial insurance plans, 2024-2025. Health Affairs. 2025.
2. Feldman CH et al. Prior authorization approval rates and appeal outcomes for obesity pharmacotherapy. JAMA Network Open. 2025.
3. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT trial). New England Journal of Medicine. 2023;389:2221-2232.
4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205-216.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384:989-1002.
6. Kaiser Family Foundation. External review of health insurance claim denials: state programs and outcomes. 2024.
7. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2024.
8. U.S. Food and Drug Administration. Drug shortage database: semaglutide injection. Accessed April 2026.
9. Novo Nordisk. Wegovy (semaglutide) prescribing information. Revised March 2024.
10. Express Scripts. National preferred formulary drug list. 2026 edition.
11. eviCore healthcare. Clinical guidelines: GLP-1 receptor agonists for weight management. 2025.
12. American College of Gastroenterology. Obesity management guidelines. 2022.
13. Cigna. Evernorth and Express Scripts integration: formulary changes and prior authorization updates. 2024.
14. Federal Food, Drug, and Cosmetic Act. Section 503A: pharmacy compounding. 21 U.S.C. § 353a.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Saxenda are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Express Scripts and Evernorth are registered trademarks of Cigna. eviCore is a registered trademark of Evernorth. Weight Watchers, Noom, Jenny Craig, Alli, and Xenical are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.